Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $51.21

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fifteen brokerages that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $51.21.

Several research firms have issued reports on KYMR. Wolfe Research upgraded shares of Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price target on the stock in a research report on Monday, August 26th. UBS Group cut their target price on Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Oppenheimer lifted their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Friday, September 27th. Wells Fargo & Company upped their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an "equal weight" rating in a research note on Monday, August 12th. Finally, Guggenheim raised their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a report on Friday, November 1st.

Insider Activity

In related news, Director Pamela Esposito sold 13,500 shares of the business's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Pamela Esposito sold 13,500 shares of the firm's stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KYMR. Values First Advisors Inc. purchased a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $61,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock valued at $114,000 after acquiring an additional 504 shares during the last quarter. Comerica Bank grew its position in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company's stock valued at $134,000 after acquiring an additional 400 shares during the period. Public Employees Retirement Association of Colorado purchased a new stake in shares of Kymera Therapeutics during the 2nd quarter worth approximately $139,000. Finally, Quest Partners LLC raised its holdings in shares of Kymera Therapeutics by 1,402.0% in the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company's stock worth $156,000 after purchasing an additional 4,865 shares during the period.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR traded up $1.09 during trading on Friday, reaching $50.95. The company had a trading volume of 300,187 shares, compared to its average volume of 368,128. The firm's fifty day moving average is $47.06 and its 200 day moving average is $41.16. The firm has a market capitalization of $3.30 billion, a PE ratio of -21.77 and a beta of 2.21. Kymera Therapeutics has a twelve month low of $13.85 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.01. The firm had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm's quarterly revenue was down 20.9% on a year-over-year basis. During the same period last year, the company posted ($0.90) EPS. Equities analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.